Andrew Cakana
Overview
Explore the profile of Andrew Cakana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al.
J Clin Oncol
. 2012 Oct;
31(2):247-55.
PMID: 23091109
Purpose: Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine whether addition of cyclophosphamide to this regimen (VTDC) could further...
12.
Moreau P, Karamanesht I, Domnikova N, Kyselyova M, Vilchevska K, Doronin V, et al.
Clin Pharmacokinet
. 2012 Sep;
51(12):823-9.
PMID: 23018466
Background And Objectives: The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM) and, in the US, for the treatment of mantle cell lymphoma following at least...
13.
Fennell D, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, et al.
J Thorac Oncol
. 2012 Aug;
7(9):1466-70.
PMID: 22895144
Based on promising preclinical efficacy of bortezomib in mesothelioma, a single-arm phase II trial (Ireland Cooperative Oncology Research Group 05-10 study), with Simon's two-stage design, was undertaken to assess efficacy...
14.
Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, et al.
Haematologica
. 2012 Jun;
97(12):1925-8.
PMID: 22689676
The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma. The initial report demonstrated non-inferior efficacy...
15.
Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al.
J Clin Oncol
. 2012 May;
30(20):2475-82.
PMID: 22585692
Purpose: This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM)...
16.
Delforge M, Dhawan R, Robinson Jr D, Meunier J, Regnault A, Esseltine D, et al.
Eur J Haematol
. 2012 Apr;
89(1):16-27.
PMID: 22469559
Objectives: The phase 3 VISTA study (ClinicalTrials.gov NCT00111319) in transplant-ineligible myeloma patients demonstrated superior efficacy with bortezomib-melphalan-prednisone (VMP; nine 6-wk cycles) vs. melphalan-prednisone (MP) but also increased toxicity. Health-related quality...
17.
Reece D, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al.
Blood
. 2011 May;
118(4):865-73.
PMID: 21562045
This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase 1 testing (1.6 mg/m² once weekly...
18.
Richardson P, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, et al.
Br J Haematol
. 2011 Mar;
153(2):212-21.
PMID: 21375521
Although haematological toxicities, such as anaemia, are common in multiple myeloma (MM), no clear consensus exists on the use and impact of erythropoiesis-stimulating agents (ESA) on outcomes in MM. This...
19.
Delforge M, Terpos E, Richardson P, Shpilberg O, Khuageva N, Schlag R, et al.
Eur J Haematol
. 2011 Mar;
86(5):372-84.
PMID: 21366694
Objectives: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated...
20.
Dimopoulos M, Mateos M, Richardson P, Schlag R, Khuageva N, Shpilberg O, et al.
Eur J Haematol
. 2010 Sep;
86(1):23-31.
PMID: 20874823
Objectives: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients...